Gabriel Mezzano

PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study

Adrià Juanola, Gabriel Mezzano, Elisa Pose, Maria José Moreta et autres

Background & Aims: Impaired phagocytic capacity due to activation of the PD-1/PD-L1 pathway has been implicated in the development of bacterial infections in patients with cirrhosis. Soluble PD-L1 (sPD-L1) is easily measurable in plasma and has been proposed as a biomarker of …

es, cl, it, dk, de, nl, fr, gb, be, us (code pays fourni par la source)

Development of a novel deep learning method that transforms tabular input variables into images for the prediction of SLD

Gabriel Cubillos, Javier Perez-Valenzuela, Herman Aguirre, Luz Ángela Martínez et autres

Steatotic liver disease (SLD), formerly named fatty liver disease, has a prevalence estimated at 30-38% in adults. Detection of SLD is important, since prompt initiation of treatment can stop disease progression, lead to a reduction in adverse outcomes, and reduce the economic …

cl (code pays fourni par la source)

Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines

Manuel Mendizábal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz et autres

The 2024 WHO guidelines for chronic hepatitis B (CHB) aim to expand and simplify treatment eligibility. We aimed to estimate treatment eligibility and uptake according to country-specific guidelines and evaluate treatment expansion based on the WHO guidelines. Treatment-naïve CHB patients from Argentina, …

ar, cl, uy, br (code pays fourni par la source)

THU-350-YI Impact of non-classical phenotypes of primary biliary cholangitis on treatment response and long-term prognosis. Results from the ColHai registry

Pinelopi Arvaniti, Helena Hernandéz Evole, Magdalena Salcedo, Ignasi Olivas et autres

OS-086 Evaluation of the response criteria following second-line treatment with bezafibrate in patients with primary biliary cholangitis

Helena Hernández-Évole, Ignasi Olivas, Nerea Quintans, Cristina Montón et autres

OP-3 ASSESSING TREATMENT ELIGIBILITY EXPANSION UNDER THE 2024 WHO GUIDELINES FOR CHRONIC HEPATITIS B

Manuel Mendizábal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz et autres

Conflict of interest: No Introduction and Objectives: The 2024 WHO guidelines for chronic hepatitis B (CHB) aim to expand and simplify treatment eligibility, but these criteria have not been assessed. We aimed to estimate treatment eligibility and uptake according to country-specific guidelines …

THU-170-YI Paris II criteria are better than Poise to predict liver-related complications after second line therapy in patients with primary biliary cholangitis

Helena Hernández‐Évole, Ignasi Olivas, Álvaro Giménez‐Manzorro, Margarita Sala Llinás et autres

THU-056 Soluble PD-L1 levels as predictors of ACLF in decompensated cirrhosis: findings from two independent cohorts

Adrià Juanola, Gabriel Mezzano, Elisa Pose, Maria José Moreta et autres

Active alcohol consumption is associated with acute-on-chronic liver failure in Hispanic patients

Francisco Idalsoaga, Luis Antonio Díaz, Eduardo Fuentes–López, Gustavo Ayares et autres

cl (code pays fourni par la source)

P- 36 ACUTE ON CHRONIC LIVER FAILURE IN LATIN AMERICA: SUB-ANALYSIS OF A SYSTEMATIC REVIEW AND META-ANALYSIS

Gabriel Mezzano, Herman Aguirre, Javier Perez-Valenzuela, Aaron Cortes et autres

Acute-on-chronic liver failure (ACLF) is characterized by acute decompensation of liver cirrhosis associated with extrahepatic organ failure, and high short-term mortality. Previous studies have estimated a global prevalence of 35% with a mortality of up to 58% at 90 days of follow-up. …

cl, es, us (code pays fourni par la source)

O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS

Luis Antonio Díaz, Sérgio Britto Garcia, Rayan Khan, Gustavo Ayares et autres

Although the WHO strategy aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030, national strategies are variable worldwide. This study aimed to assess the establishment of different policies and strategies to eliminate HCV in the Americas. …

cl, ca, us, gt, ar, bo, br (code pays fourni par la source)

Prevalencia y caracterización de pacientes con esteatosis hepática en una Unidad de Medicina Preventiva: Estudio observacional, de corte transversal

Javier Pérez-Valenzuela, Herman Aguirre, Luz Ángela Martínez, Lorena Castro et autres

Introducción: La esteatosis hepática es la enfermedad hepática crónica más frecuente a nivel mundial con prevalencia de 30-38%, asociándose al desarrollo de esteatohepatitis, fibrosis, cirrosis y hepatocarcinoma.Recientemente se publicó una nueva terminología para esta condición, clasificándola en 5 grupos.El objetivo de nuestro …

cl (code pays fourni par la source)